
Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the…
The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with…
Find out why coffee is so good for you and hear the team sing Baby…
Major changes to the way immunotherapy drugs are researched and evaluated are essential if they…
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals,…
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase…
Patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) have few treatment options when they are…
Researchers at Fox Chase Cancer Center, USA, along with an international team of investigators, have…
Front-line therapy with the immune checkpoint inhibitor pembrolizumab doubled progression-free survival vs chemotherapy in patients…